Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors -

Published: February 2014 | Pages: 67 | Format: PDF and Online

The present Competitive Intelligence Report about CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting CD20 for treatment of B-cell mediated malignancies and rheumatoid arthritis as of February 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The chimeric anti-CD20 antibody rituximab (Rituxan / MabThera) from Biogen Idec and Roche is one of the world’s commercially most successful antibodies (2013 sales of over US$ 7.7 bln). Rituximab was first approved in 1997 by the FDA for treatment of B-cell malignancies and in 2006 for 3rd line therapy of rheumatoid arthritis. Sales of rituximab for treatment of rheumatoid athritis makes out 17.1% of total Rituxan (US) / MabThera (EU) sales.Genentech, Roche and Biogen Idec have stepwise expanded the indication label of rituximab and are developing 2nd and 3rd generation CD20 antibodies as a measure to protect against emerging rituximab biosimilars. In fact, second generation anti-CD20 antibody Gazyva has already been approved and launched in ist first indication.

The commercial attractiveness of rituximab has stimulated many companies to create and develop next generation anti-CD20 monoclonal antibodies with improved properties compared with the chimeric antibody rituximab. The forthcoming patent expiry for Rituxan / MabThera has boosted interest in and activties for developing biosimilar copies with the most advanced projects already approved and marketed in off-patent countries, but also in phase III studies in Western regulated markets.

The report includes a compilation of currently active projects in development of CD20 targeting antibodies for treatment of hematologic malignancies and rheumatoid arthritis and other autoimmune diseases. In addition, the report lists company-specific R&D pipelines of CD20 antibodies. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.


Table of Contents 

1. CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors 

Marketed CD20 Antibodies & Sales
-           Rituxan/MabThera Pipeline & Sales
-           Arzerra Pipeline & Sales
-           Gazyva Pipeline & Sales
-           Bexxar & Zevalin Pipeline & Sales

Biosuperior CD20 Antibodies 

Biosimilar CD20 Antibodies
-           Rituxan/MabThera (rituximab) Biosimilars
-           Arzerra (ofatumumab) Biosimilars

2.  Corporate CD20 Antibody Biosimilar & Biobetter Pipelines